BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 15854132)

  • 1. Apoptosis in CD30-positive lymphoproliferative disorders of the skin.
    Greisser J; Doebbeling U; Roos M; Mueller B; Schmid M; Burg G; Kadin ME; Kempf W
    Exp Dermatol; 2005 May; 14(5):380-5. PubMed ID: 15854132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MUM1 expression in cutaneous CD30+ lymphoproliferative disorders: a valuable tool for the distinction between lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.
    Kempf W; Kutzner H; Cozzio A; Sander CA; Pfaltz MC; Müller B; Pfaltz M
    Br J Dermatol; 2008 Jun; 158(6):1280-7. PubMed ID: 18410414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of chemokines and chemokine receptors in cutaneous CD30+ lymphoproliferative disorders.
    Yamaguchi T; Ohshima K; Karube K; Kawano R; Nakayama J; Suzumiya J; Kikuchi M
    Br J Dermatol; 2006 May; 154(5):904-9. PubMed ID: 16634894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apoptotic and proliferating cells in cutaneous lymphoproliferative diseases.
    Kikuchi A; Nishikawa T
    Arch Dermatol; 1997 Jul; 133(7):829-33. PubMed ID: 9236520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic and prognostic evaluation of phenotypic markers TRAF1, MUM1, BCL2 and CD15 in cutaneous CD30-positive lymphoproliferative disorders.
    Benner MF; Jansen PM; Meijer CJ; Willemze R
    Br J Dermatol; 2009 Jul; 161(1):121-7. PubMed ID: 19416236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathobiology of CD30+ cutaneous T-cell lymphomas.
    Kadin ME
    J Cutan Pathol; 2006 Feb; 33 Suppl 1():10-7. PubMed ID: 16412208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary and secondary cutaneous Ki-1+ (CD30+) anaplastic large cell lymphomas. Morphologic, immunohistologic, and clinical-characteristics.
    Kaudewitz P; Stein H; Dallenbach F; Eckert F; Bieber K; Burg G; Braun-Falco O
    Am J Pathol; 1989 Aug; 135(2):359-67. PubMed ID: 2551170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FOXP3 positive regulatory T-cells in cutaneous and systemic CD30 positive T-cell lymphoproliferations.
    Gjerdrum LM; Woetmann A; Odum N; Hother C; Henrik-Nielsen R; Gniadecki R; Ralfkiaer E
    Eur J Haematol; 2008 Jun; 80(6):483-9. PubMed ID: 18331599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. c-Jun expression and activation are restricted to CD30+ lymphoproliferative disorders.
    Drakos E; Leventaki V; Schlette EJ; Jones D; Lin P; Medeiros LJ; Rassidakis GZ
    Am J Surg Pathol; 2007 Mar; 31(3):447-53. PubMed ID: 17325487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cutaneous CD30+ lymphoproliferative disorders: expression of bcl-2 and proteins of the tumor necrosis factor receptor superfamily.
    Paulli M; Berti E; Boveri E; Kindl S; Bonoldi E; Gambini C; Rosso R; Borroni G; Straccapansa V; Magrini U; DeCoteau JE; Krammer PH; Möller P; Kadin ME
    Hum Pathol; 1998 Nov; 29(11):1223-30. PubMed ID: 9824099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD30+ lymphoproliferative disorders: histopathology, differential diagnosis, new variants, and simulators.
    Kempf W
    J Cutan Pathol; 2006 Feb; 33 Suppl 1():58-70. PubMed ID: 16412214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cutaneous CD30-positive lymphoproliferative disorders with CD8 expression: a clinicopathologic study of 21 cases.
    Plaza JA; Feldman AL; Magro C
    J Cutan Pathol; 2013 Feb; 40(2):236-47. PubMed ID: 23189966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of expression of 5-hydroxymethylcytosine in CD30-positive cutaneous lymphoproliferative disorders.
    De Souza A; Tinguely M; Pfaltz M; Burghart DR; Kempf W
    J Cutan Pathol; 2014 Dec; 41(12):901-6. PubMed ID: 25353265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Borderline CD30+ cutaneous lymphoproliferative disorder: report of a case with expression of cytotoxic markers and response to clarithromycin.
    Ponte P; Serrão V; Viana I; Vale E; João A; Cerroni L
    J Cutan Pathol; 2011 Mar; 38(3):301-5. PubMed ID: 19922478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The expression of MUM1 in cutaneous T-cell lymphoproliferative disorders.
    Wasco MJ; Fullen D; Su L; Ma L
    Hum Pathol; 2008 Apr; 39(4):557-63. PubMed ID: 18234282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angioinvasive lymphomatoid papulosis: a new variant simulating aggressive lymphomas.
    Kempf W; Kazakov DV; Schärer L; Rütten A; Mentzel T; Paredes BE; Palmedo G; Panizzon RG; Kutzner H
    Am J Surg Pathol; 2013 Jan; 37(1):1-13. PubMed ID: 23026936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of clonal rearrangement of T-cell receptor genes in the diagnosis of primary cutaneous CD30 lymphoproliferative disorders.
    Greisser J; Palmedo G; Sander C; Kutzner H; Kazakov DV; Roos M; Burg G; Kempf W
    J Cutan Pathol; 2006 Nov; 33(11):711-5. PubMed ID: 17083688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cutaneous T-cell lymphomas (including rare subtypes). Current concepts. II.
    Paulli M; Berti E
    Haematologica; 2004 Nov; 89(11):1372-88. PubMed ID: 15531460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Large CD30-positive cells in benign, atypical lymphoid infiltrates of the skin.
    Werner B; Massone C; Kerl H; Cerroni L
    J Cutan Pathol; 2008 Dec; 35(12):1100-7. PubMed ID: 18616762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apoptosis and proliferation in subcutaneous panniculitis-like T-cell lymphoma.
    Sen F; Rassidakis GZ; Jones D; Medeiros LJ
    Mod Pathol; 2002 Jun; 15(6):625-31. PubMed ID: 12065776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.